Frontlight ResearchEarly access
Active, not recruitingPhase 3
A study to test trimodulin in adult hospitalized patients with severe pneumonia
Key facts
- Who runs it
- Biotest GmbH & Co. KGaA
- Where
- Austria, Belgium, Czechia, France, Germany, Hungary, Ireland, Romania, and Spain56 sites in 9 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 275 people, planned
- Started
- 7 Jun 2023
- Expected to end
- 29 Dec 2028
- Type of study
- Interventional
- Record updated
- 20 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- Written informed consent obtained from subject or legally acceptable/authorized representative (LAR)
- Hospitalized, adult (≥ 18 years of age) subject (any gender)
- C-reactive protein (CRP) ≥ 70 mg/L up to 1 calendar day prior to start of treatment with IMP
- Diagnosis of active community-acquired pneumonia (CAP) before hospital-admission or within 48 hours after admission
- Radiological (or other imaging technology) evidence consistent with active pneumonia must be available from routine SoC
- Acute respiratory failure requiring IMV, defining sCAP (Appendix 9: sCAP Diagnostic Criteria According to the ATS/IDSA Guideline)
- Treatment with IMP must be started between 1 and 24 hours after initiation of IMV
- Subject must receive SoC treatment for sCAP according to applicable regional and global sCAP guidelines
Who cannot take part
- Selective IgA deficiency with known antibodies to IgA
- Treatment with > 1 g/kg body weight of polyvalent immunoglobulin preparation in total during the last 21 days before start of IMP treatment
- Treatment with fluoroquinolone preparations, during the last 2 days before start of IMP treatment
- Hematopoietic stem cell transplantation within 1 year, or previous lung transplantation
- Treatment with investigational medications procedures not according to SoC of the trial site , due to participation in another interventional clinical tria within 30 days before start of IMP treatment or previous IMP treatment with IMP in this clinical trial
- Subjects discharged from hospital within the previous 14 days
- Thromboembolic events (TEEs) caused by other reasons than the current sCAP (e.g., cerebrovascular accidents, transient ischemic attack, myocardial infarction, pulmonary embolism, and deep vein thrombosis) within 3 months before start of IMP treatment.. unless the risk for further TEEs can be adequately managed with standard prophylaxis or treatment
- Pre-existing severe lung diseases concomitant to current sCAP (e.g., subjects with active tuberculosis, or active lung cancer)
- Life expectancy of less than 90 days, according to the investigator’s clinical judgment, because of medical conditions related neither to sCAP nor to sCAP-associated septic conditions
- Pre-existing hemolytic disease
- End-stage renal disease (ESRD) or known primary focal segmental glomerulosclerosis (FSGS)
- Pre-existing decompensated heart failure (New York Heart Association class III–IV)
- Pre-existing severe hepatic cirrhosis, (Child Pugh score ≥ 10 points), or severe hepatic impairment (Child Pugh score ≥ 10 points), or hepatocellular carcinoma
- Known intolerance to proteins of human origin or known allergic reactions to any of the components of trimodulin / placebo
- Severe neutropenia (neutrophil count <500/mm³) per most recent test performed up to 1 calendar day prior to start of IMP treatment
- Thrombocytopenia (platelet count <30,000/mm³) per most recent test performed up to 1 calendar day prior to start of IMP treatment
- Hemoglobin (Hb) < 7 g/dL hours per most recent test performed up to 1 calendar day prior to start of IMP treatment
- Severe renal impairment, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² per most recent test performed up to 1 calendar day prior to start of IMP treatment (details in Appendix 2: Estimated Glomerular Filtration Rate).*), unless the subject is already on dialysis or continuous replacement therapy
- For an incapacitated subject: any indication that the subject’s presumed will would be against inclusion in the trial
- Pregnant or lactating women
- Morbid obesity with high body mass index (BMI) ≥ 40 kg/m2, or malnutrition with low BMI < 16 kg/m2
- Employee or direct relative of an employee of the CRO, or the trial site, if employee is directly involved in the trial or otherwise in a dependent relationship with the site staff
- Persons, subject to legal protection measures, if applicable according to local laws
- Subjects of childbearing potential not willing to use reliable contraceptive measures during the trial and for 15 weeks after the last IMP treatment
- Subjects on extracorporeal membrane oxygenation (ECMO) at start of IMP treatment
- Suspected hospital-acquired pneumonia (HAP) including ventilator associated pneumonia (VAP)
This trial has no sites in United States.
It has sites in 9 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess the efficacy of trimodulin based on 28-day all-cause mortality to demonstrate superiority to treatment with placebo
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with severe community-acquired pneumonia (sCAP)
- Record updated
- 20 July 2026